Preview Of Arena's Upcoming Advisory Committee

By Markus Aarnio:Arena Pharmaceuticals (ARNA) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs-- an important class of validated drug targets-- in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

By KLLJ Investments: Arena Pharmaceuticals (ARNA) investors have had a tough road over the last 12 months since a negative vote by an Advisory Committee called to review Arena’s lead drug candidate for the treatment of obesity – lorcaserin. The stock was trading close to $7.00 a year ago heading into that fateful Advisory Committee, down to under $2 after a negative vote foreshadowed a Complete Response Le

Zacks.com submits: Orexigen Therapeutics Inc. (OREX) was dealt a severe blow by the U.S. Food and Drug Administration (FDA) when the regulatory body declined to approve its obesity drug, Contrave in the present form and issued a complete response letter (CRL).

By The Burrill Report: By Michael Fitzhugh

By M.E. Garza: We anticipate that shares of Arena Pharmaceuticals (ARNA) will continue to creep up after Analysts at Piper Jaffray have upgraded the firm and raised the share price target from $1.50 to $3.

EP Vantage submits:In the end the FDA’s rejection of Arena Pharmaceuticals’ (ARNA) Lorqess weight-loss drug was more damning than predicted.

Prohost Biotech submits:This Thursday an FDA advisory panel will discuss Arena’s (ARNA) drug Lorqess (lorcaserin) for obesity.

Joseph Krueger submits: Before the FDA review panel’s of Vivus’s (VVUS) drug Qnexa, I expressed significant doubt that the panel review would be positive based primarily on the safety issues surrounding one of its ingredients topiramate here.